news aktuell GmbH

Acousia Therapeutics to present its clinical Phase 2 PROHEAR study on hearing loss treatment candidate ACOU085 at upcoming conferences12.8.2024 09:00:00 CEST | news aktuell GmbH

Tübingen, Germany, August 12, 2024 Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, will be presenting the ACOU085 Phase 2 PROHEAR clinical study at the HansonWade 4th Inner Ear Disorders Therapeutics Summit in Boston (MA) from August 20–22, and at the 36th World Congress of Audiology from September 19–22, 2024.
  • 1
  • 2
  • 3
  • 4
  • 5
  • Sista
  • >>
HiddenA line styled icon from Orion Icon Library.Eye